{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T05:26:49Z","timestamp":1738474009852,"version":"3.35.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10549-024-07554-w","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T18:01:01Z","timestamp":1731693661000},"page":"215-225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trajectories of antidepressant use after tamoxifen initiation among young and middle-aged women with breast cancer"],"prefix":"10.1007","volume":"210","author":[{"given":"Oluwadamilola","family":"Onasanya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Rosenblatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"dosReis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eberechukwu","family":"Onukwugha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafar","family":"Zafari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Camelo Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"issue":"3","key":"7554_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10549-013-2708-6","volume":"141","author":"L Tofteg\u00e5rd Andersen","year":"2013","unstructured":"Tofteg\u00e5rd Andersen L, Voigt Hansen M, Rosenberg J, G\u00f6genur I (2013) Pharmacological treatment of depression in women with breast cancer: a systematic review. Breast Cancer Res Treat 141(3):325\u2013330. https:\/\/doi.org\/10.1007\/s10549-013-2708-6","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"7554_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3109\/0284186X.2010.531049","volume":"50","author":"NP Suppli","year":"2011","unstructured":"Suppli NP, Deltour I, Damkjaer LH et al (2011) Factors associated with the prescription of antidepressive medication to breast cancer patients. Acta Oncol 50(2):243\u2013251. https:\/\/doi.org\/10.3109\/0284186X.2010.531049","journal-title":"Acta Oncol"},{"issue":"8","key":"7554_CR3","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S et al (2019) Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol 30(8):1194\u20131220. https:\/\/doi.org\/10.1093\/annonc\/mdz173","journal-title":"Ann Oncol"},{"key":"7554_CR4","unstructured":"Guidelines Detail. NCCN. https:\/\/www.nccn.org\/guidelines\/guidelines-detail. Accessed October 18, 2022."},{"issue":"1","key":"7554_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/annonc\/mdx526","volume":"29","author":"L Grassi","year":"2018","unstructured":"Grassi L, Nanni MG, Rodin G, Li M, Caruso R (2018) The use of antidepressants in oncology: a review and practical tips for oncologists. Ann Oncol 29(1):101\u2013111. https:\/\/doi.org\/10.1093\/annonc\/mdx526","journal-title":"Ann Oncol"},{"key":"7554_CR6","unstructured":"Research C for DE and. Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers. FDA. June 2023. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Accessed July 25, 2023."},{"key":"7554_CR7","doi-asserted-by":"publisher","unstructured":"Haque R, Shi J, Schottinger JE et al (2016) Tamoxifen and antidepressant drug interaction among a cohort of 16 887 breast cancer survivors. JNCI: J  National Cancer Institute 108(3):djv337. https:\/\/doi.org\/10.1093\/jnci\/djv337","DOI":"10.1093\/jnci\/djv337"},{"key":"7554_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c693","volume":"340","author":"CM Kelly","year":"2010","unstructured":"Kelly CM, Juurlink DN, Gomes T et al (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340:c693. https:\/\/doi.org\/10.1136\/bmj.c693","journal-title":"BMJ"},{"issue":"2","key":"7554_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10549-016-3928-3","volume":"159","author":"A Valachis","year":"2016","unstructured":"Valachis A, Garmo H, Weinman J et al (2016) Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study. Breast Cancer Res Treat 159(2):293\u2013303. https:\/\/doi.org\/10.1007\/s10549-016-3928-3","journal-title":"Breast Cancer Res Treat"},{"key":"7554_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2021.10.003","author":"M Bradbury","year":"2021","unstructured":"Bradbury M, Hutton B, Beltran-Bless AA et al (2021) Time to update evidence-based guideline recommendations about concurrent tamoxifen and antidepressant use? A systematic review. Clinical Breast Cancer. https:\/\/doi.org\/10.1016\/j.clbc.2021.10.003","journal-title":"Clin Breast Cancer"},{"key":"7554_CR11","doi-asserted-by":"publisher","unstructured":"Oliveira LM de, Garcia HO, Curvello KD, Rebelatto TF, Pizzol T da SD (2023) Letter to the Editor of Clinical Breast Cancer, on \u201cTime to Update Evidence-Based Guideline Recommendations About Concurrent Tamoxifen and Antidepressant Use? A Systematic Review,\u201d Conducted by Michelle Bradbury and Collaborators and Published in Clinical Breast Cancer April Vol 22 no.4 e362-e373, 2022. Clinical Breast Cancer. 2023;23(3):e109\u2013e111. https:\/\/doi.org\/10.1016\/j.clbc.2022.12.018","DOI":"10.1016\/j.clbc.2022.12.018"},{"key":"7554_CR12","unstructured":"Guidelines Detail. NCCN. https:\/\/www.nccn.org\/guidelines\/guidelines-detail. Accessed November 11, 2022."},{"key":"7554_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","volume":"6","author":"DS Nagin","year":"2010","unstructured":"Nagin DS, Odgers CL (2010) Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol 6:109\u2013138. https:\/\/doi.org\/10.1146\/annurev.clinpsy.121208.131413","journal-title":"Annu Rev Clin Psychol"},{"issue":"9","key":"7554_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/MLR.0b013e3182984c1f","volume":"51","author":"JM Franklin","year":"2013","unstructured":"Franklin JM, Shrank WH, Pakes J et al (2013) Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence. Med Care 51(9):789\u2013796. https:\/\/doi.org\/10.1097\/MLR.0b013e3182984c1f","journal-title":"Med Care"},{"issue":"1","key":"7554_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s10549-012-2330-z","volume":"137","author":"SB Dusetzina","year":"2013","unstructured":"Dusetzina SB, Alexander GC, Freedman RA, Huskamp HA, Keating NL (2013) Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004\u20132010. Breast Cancer Res Treat 137(1):285\u2013296. https:\/\/doi.org\/10.1007\/s10549-012-2330-z","journal-title":"Breast Cancer Res Treat"},{"key":"7554_CR16","doi-asserted-by":"publisher","unstructured":"Onasanya O, dosReis S, Damachi U, Camelo Castillo W (2023) Antidepressant adherence trajectory before cancer diagnosis and risk of antidepressant discontinuation after cancer diagnosis among middle-aged US adults. JCO 41(16_suppl):e18890\u2013e18890. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e18890","DOI":"10.1200\/JCO.2023.41.16_suppl.e18890"},{"issue":"3","key":"7554_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10549-020-05549-x","volume":"180","author":"L Lambert-C\u00f4t\u00e9","year":"2020","unstructured":"Lambert-C\u00f4t\u00e9 L, Bouhnik AD, Bendiane MK et al (2020) Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases. Breast Cancer Res Treat 180(3):777\u2013790. https:\/\/doi.org\/10.1007\/s10549-020-05549-x","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"7554_CR18","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/pds.4751","volume":"28","author":"HE Tervonen","year":"2019","unstructured":"Tervonen HE, Daniels B, Tang M, Preen DB, Pearson SA (2019) Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients. Pharmacoepidemiol Drug Saf 28(6):812\u2013820. https:\/\/doi.org\/10.1002\/pds.4751","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"7554_CR19","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/pds.4012","volume":"25","author":"AN Winn","year":"2016","unstructured":"Winn AN, Dusetzina SB (2016) The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer. Pharmacoepidemiol Drug Saf 25(8):953\u2013959. https:\/\/doi.org\/10.1002\/pds.4012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7554_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-07205-6","author":"CY Chang","year":"2024","unstructured":"Chang CY, Jones BL, Hincapie-Castillo JM et al (2024) Association between trajectories of prescription opioid use and risk of opioid use disorder and overdose among US nonmetastatic breast cancer survivors. Breast Cancer Res Treat. https:\/\/doi.org\/10.1007\/s10549-023-07205-6","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"7554_CR21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10549-010-0869-0","volume":"124","author":"BL Sprague","year":"2010","unstructured":"Sprague BL, Trentham-Dietz A, Nichols HB, Hampton JM, Newcomb PA (2010) Change in lifestyle behaviors and medication use after a diagnosis of ductal carcinoma in situ. Breast Cancer Res Treat 124(2):487\u2013495. https:\/\/doi.org\/10.1007\/s10549-010-0869-0","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"7554_CR22","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1007\/s00520-022-06827-8","volume":"30","author":"ZM Nakamura","year":"2022","unstructured":"Nakamura ZM, Damone EM, Herrick HP et al (2022) Anticipating mental health needs after chemotherapy in early-stage breast cancer using patient-reported symptom screening. Support Care Cancer 30(5):3933\u20133941. https:\/\/doi.org\/10.1007\/s00520-022-06827-8","journal-title":"Support Care Cancer"},{"issue":"5","key":"7554_CR23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/pon.3606","volume":"24","author":"MJ Fisch","year":"2015","unstructured":"Fisch MJ, Zhao F, Manola J, Miller AH, Pirl WF, Wagner LI (2015) Patterns and predictors of antidepressant use in ambulatory cancer patients with common solid tumors. Psychooncology 24(5):523\u2013532. https:\/\/doi.org\/10.1002\/pon.3606","journal-title":"Psychooncology"},{"issue":"4","key":"7554_CR24","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.genhosppsych.2013.03.017","volume":"35","author":"JC Reece","year":"2013","unstructured":"Reece JC, Chan YF, Herbert J, Gralow J, Fann JR (2013) Course of depression, mental health service utilization and treatment preferences in women receiving chemotherapy for breast cancer. Gen Hosp Psychiatry 35(4):376\u2013381. https:\/\/doi.org\/10.1016\/j.genhosppsych.2013.03.017","journal-title":"Gen Hosp Psychiatry"},{"issue":"6","key":"7554_CR25","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/pds.4198","volume":"26","author":"YT Chou","year":"2017","unstructured":"Chou YT, Winn AN, Rosenstein DL, Dusetzina SB (2017) Assessing disruptions in adherence to antidepressant treatments after breast cancer diagnosis. Pharmacoepidemiol Drug Saf 26(6):676\u2013684. https:\/\/doi.org\/10.1002\/pds.4198","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7554_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.5114","volume":"29","author":"ICPE All Access conference abstracts","year":"2020","unstructured":"ICPE All Access conference abstracts (2020) Pharmacoepidemiol Drug Saf 29:3\u2013634. https:\/\/doi.org\/10.1002\/pds.5114","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7554_CR27","unstructured":"IQVIA PharMetrics\u00ae Plus. https:\/\/www.iqvia.com\/library\/fact-sheets\/iqvia-pharmetrics-plus. Accessed May 20, 2022."},{"issue":"5","key":"7554_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10552-007-0131-1","volume":"18","author":"S Setoguchi","year":"2007","unstructured":"Setoguchi S, Solomon DH, Glynn RJ, Cook EF, Levin R, Schneeweiss S (2007) Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control 18(5):561\u2013569. https:\/\/doi.org\/10.1007\/s10552-007-0131-1","journal-title":"Cancer Causes Control"},{"issue":"11","key":"7554_CR29","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1634\/theoncologist.2011-0121","volume":"16","author":"G Braems","year":"2011","unstructured":"Braems G, Denys H, De Wever O, Cocquyt V, Van den Broecke R (2011) Use of tamoxifen before and during pregnancy. Oncologist 16(11):1547\u20131551. https:\/\/doi.org\/10.1634\/theoncologist.2011-0121","journal-title":"Oncologist"},{"issue":"2\u20133","key":"7554_CR30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000360229","volume":"65","author":"DS Nagin","year":"2014","unstructured":"Nagin DS (2014) Group-based trajectory modeling: an overview. Ann Nutr Metab 65(2\u20133):205\u2013210. https:\/\/doi.org\/10.1159\/000360229","journal-title":"Ann Nutr Metab"},{"issue":"3","key":"7554_CR31","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/0049124101029003005","volume":"29","author":"BL Jones","year":"2001","unstructured":"Jones BL, Nagin DS, Roeder K (2001) A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res 29(3):374\u2013393. https:\/\/doi.org\/10.1177\/0049124101029003005","journal-title":"Sociol Methods Res"},{"issue":"5","key":"7554_CR32","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/1467-8624.00086","volume":"70","author":"D Nagin","year":"1999","unstructured":"Nagin D, Tremblay RE (1999) Trajectories of boys\u2019 physical aggression, opposition, and hyperactivity on the path to physically violent and nonviolent juvenile delinquency. Child Dev 70(5):1181\u20131196. https:\/\/doi.org\/10.1111\/1467-8624.00086","journal-title":"Child Dev"},{"issue":"11","key":"7554_CR33","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s00228-016-2106-1","volume":"72","author":"AC M\u00e5rdby","year":"2016","unstructured":"M\u00e5rdby AC, Schi\u00f6ler L, Sundell KA, Bjerkeli P, Les\u00e9n E, J\u00f6nsson AK (2016) Adherence to antidepressants among women and men described with trajectory models: a Swedish longitudinal study. Eur J Clin Pharmacol 72(11):1381\u20131389. https:\/\/doi.org\/10.1007\/s00228-016-2106-1","journal-title":"Eur J Clin Pharmacol"},{"key":"7554_CR34","doi-asserted-by":"publisher","unstructured":"MacEwan JP, Forma FM, Shafrin J, Hatch A, Lakdawalla DN, Lindenmayer JP (2016) Patterns of adherence to oral atypical antipsychotics among patients diagnosed with Schizophrenia. J Manag Care Spec Pharm 22(11):1349\u20131361. https:\/\/doi.org\/10.18553\/jmcp.2016.22.11.1349","DOI":"10.18553\/jmcp.2016.22.11.1349"},{"issue":"6","key":"7554_CR35","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/cncr.27838","volume":"119","author":"TM Breslin","year":"2013","unstructured":"Breslin TM, Banerjee M, Gust C, Birkmeyer NJ (2013) Trends in advanced imaging use for women undergoing breast cancer surgery. Cancer 119(6):1251\u20131256. https:\/\/doi.org\/10.1002\/cncr.27838","journal-title":"Cancer"},{"key":"7554_CR36","unstructured":"Login. NCCN. https:\/\/www.nccn.org\/login. Accessed December 23, 2023."},{"key":"7554_CR37","unstructured":"Condition Categories - Chronic Conditions Data Warehouse. https:\/\/www2.ccwdata.org\/web\/guest\/condition-categories. Accessed November 23, 2021."},{"key":"7554_CR38","doi-asserted-by":"publisher","unstructured":"Stearns V, Johnson MD, Rae JM et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. JNCI J Natl Cancer Inst 95(23):1758\u20131764. https:\/\/doi.org\/10.1093\/jnci\/djg108","DOI":"10.1093\/jnci\/djg108"},{"issue":"8","key":"7554_CR39","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3109\/02841861003801130","volume":"49","author":"KYL Yap","year":"2010","unstructured":"Yap KYL, Ho YXX, Chui WK, Chan A (2010) Harnessing the internet cloud for managing drug interactions with chemotherapy regimens in patients with cancer suffering from depression. Acta Oncol 49(8):1235\u20131245. https:\/\/doi.org\/10.3109\/02841861003801130","journal-title":"Acta Oncol"},{"key":"7554_CR40","doi-asserted-by":"publisher","unstructured":"Jin Y, Desta Z, Stearns V, et al (2005) CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment. JNCI J National Cancer Institute 97(1):30\u201339. https:\/\/doi.org\/10.1093\/jnci\/dji005","DOI":"10.1093\/jnci\/dji005"},{"issue":"1","key":"7554_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12991-020-00306-2","volume":"19","author":"B Dell\u2019Osso","year":"2020","unstructured":"Dell\u2019Osso B, Albert U, Carr\u00e0 G et al (2020) How to improve adherence to antidepressant treatments in patients with major depression: a psychoeducational consensus checklist. Ann Gen Psychiatry 19(1):61. https:\/\/doi.org\/10.1186\/s12991-020-00306-2","journal-title":"Ann Gen Psychiatry"},{"issue":"2","key":"7554_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1590\/1516-4446-2020-0935","volume":"43","author":"M Solmi","year":"2021","unstructured":"Solmi M, Miola A, Croatto G et al (2021) How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. Braz J Psychiatry 43(2):189\u2013202. https:\/\/doi.org\/10.1590\/1516-4446-2020-0935","journal-title":"Braz J Psychiatry"},{"issue":"3","key":"7554_CR43","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s10549-014-3125-1","volume":"147","author":"W Sheridan","year":"2014","unstructured":"Sheridan W, Scott T, Caroline S et al (2014) Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time? Breast Cancer Res Treat 147(3):617\u2013629. https:\/\/doi.org\/10.1007\/s10549-014-3125-1","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"7554_CR44","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.1245\/s10434-019-07653-9","volume":"26","author":"BL Murphy","year":"2019","unstructured":"Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC (2019) Adolescents and young adults with breast cancer have more aggressive disease and treatment than patients in their forties. Ann Surg Oncol 26(12):3920\u20133930. https:\/\/doi.org\/10.1245\/s10434-019-07653-9","journal-title":"Ann Surg Oncol"},{"key":"7554_CR45","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00793","author":"EJ Cathcart-Rake","year":"2021","unstructured":"Cathcart-Rake EJ, Ruddy KJ, Bleyer A, Johnson RH (2021) Breast cancer in adolescent and young adult women under the age of 40 years. JCO Oncol Pract. https:\/\/doi.org\/10.1200\/OP.20.00793","journal-title":"JCO Oncol Pract"},{"key":"7554_CR46","doi-asserted-by":"publisher","unstructured":"Korde LA, Partridge AH, Esser M, Lewis S, Simha J, Johnson RH (2015) Breast cancer in young women: research priorities. A report of the young survival coalition research think tank meeting. J Adolescent  Young Adult Oncol 4(1):34\u201343. https:\/\/doi.org\/10.1089\/jayao.2014.0049","DOI":"10.1089\/jayao.2014.0049"},{"issue":"1","key":"7554_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2307\/2137284","volume":"36","author":"RM Andersen","year":"1995","unstructured":"Andersen RM (1995) Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav 36(1):1\u201310","journal-title":"J Health Soc Behav"},{"key":"7554_CR48","doi-asserted-by":"publisher","unstructured":"Andersen R, Newman JF (2005) Societal and individual determinants of medical care utilization in the United States. Milbank Quart 83(4). Online-only-Online-only. https:\/\/doi.org\/10.1111\/j.1468-0009.2005.00428.x","DOI":"10.1111\/j.1468-0009.2005.00428.x"},{"issue":"1","key":"7554_CR49","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10549-022-06704-2","volume":"197","author":"JM Neuner","year":"2023","unstructured":"Neuner JM, Fergestrom N, Pezzin LE, Laud PW, Ruddy KJ, Winn AN (2023) Medication delivery factors and adjuvant endocrine therapy adherence in breast cancer. Breast Cancer Res Treat 197(1):223\u2013233. https:\/\/doi.org\/10.1007\/s10549-022-06704-2","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07554-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-024-07554-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07554-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T11:10:03Z","timestamp":1738408203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-024-07554-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["7554"],"URL":"https:\/\/doi.org\/10.1007\/s10549-024-07554-w","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"assertion":[{"value":"21 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Oluwadamilola Onasanya is an employee of Carelon Research, an organization that conducts contract research for life sciences companies, payers, and government agencies. Susan dosReis receives funding from GSK for work unrelated to the content of the manuscript. She also consults for Alexion Pharmaceuticals. Wendy Camelo Castillo was supported in part by a research grant from Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp, unrelated to this work. Dr. Onukwugha receives funding from Organon for work unrelated to the content of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The University of Maryland Baltimore Institutional Review Board deemed this study exempt.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The content expressed in this paper is solely the responsibility of the authors and does not necessarily represent the official view of the National Cancer Institute. The statements, findings, conclusions, views, and opinions contained and expressed in this manuscript are based in part on data obtained under license from IQVIA. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IQVIA or any of its affiliated or subsidiary entities. Source: IQVIA PharMetrics\u00ae Plus for Academics, January 2006\u2013December 2022. All Rights Reserved.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}